Mizuho Medy Co., Ltd. (4595) AI Stock Analysis

• Market Cap: ¥35.07B
• Dividend Yield: 6.29%
• Average Volume (3M): 64.11K
• Price to Earnings (P/E): 9.5
• Beta (1Y): 0.45
• Revenue Growth: -12.03%
• EPS Growth: -19.61%
• Country: JP
• Employees: 187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 96.42
• Shares Outstanding: 19,051,200
• 10 Day Avg. Volume: 72,640
• 30 Day Avg. Volume: 64,113
• PEG Ratio: -1.03
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 2.88
• P/FCF Ratio: 19.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 169.6
• Revenue Forecast (FY): ¥10.80B

• Rating: 81 Outperform
• Price Target: ¥2,072.00 ▲(18.20% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven primarily by strong financial quality (notably zero debt and solid profitability), supported by attractive valuation (low P/E and high dividend yield). Technicals are moderately positive with an upward trend and neutral momentum, while weaker 2025 cash flow momentum tempers the overall rating.

Positive Factors

Balance Sheet Strength

Zero reported debt and an improving equity base give Mizuho Medy durable financial flexibility, lowering bankruptcy and refinancing risk. This conservatism supports investment in product development or capacity, secures dividend ability, and cushions the business through cyclical swings over the next 2–6 months.

Negative Factors

Weaker Cash Conversion in 2025

A decline in operating cash flow and cash conversion in 2025 reduces free cash flow flexibility relative to earnings, tightening funding for capex, dividends or new product rollouts. If conversion weakness persists, it elevates volatility of available cash for strategic initiatives in the coming quarters.

Mizuho Medy Co., Ltd. Business Overview & Revenue Model

Company Description

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza viru...

Read more

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza viru...

How the Company Makes Money

Mizuho Medy Co., Ltd. generates revenue through the sale of its medical devices and healthcare products. The company targets hospitals, clinics, and other healthcare facilities as its primary customer base, supplying them with essential medical eq...

Read more

Mizuho Medy Co., Ltd. generates revenue through the sale of its medical devices and healthcare products. The company targets hospitals, clinics, and other healthcare facilities as its primary customer base, supplying them with essential medical eq...

Mizuho Medy Co., Ltd. Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.74B	11.26B	11.43B	10.99B	17.58B	12.89B
Gross Profit	7.63B	7.78B	8.04B	8.03B	14.05B	9.61B
EBITDA	4.80B	4.91B	5.10B	5.40B	11.26B	6.87B
Net Income	3.30B	3.42B	3.77B	3.77B	7.84B	4.82B
Balance Sheet
Total Assets	19.73B	22.38B	20.73B	18.95B	19.10B	12.19B
Cash, Cash Equivalents and Short-Term Investments	12.37B	10.82B	11.25B	10.13B	8.70B	4.33B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	2.50B	3.69B	3.37B	3.27B	4.82B	4.16B
Stockholders Equity	17.23B	18.68B	17.35B	15.68B	14.28B	8.03B
Cash Flow
Free Cash Flow	0.00	1.70B	3.05B	3.73B	5.99B	5.44B
Operating Cash Flow	0.00	1.96B	3.35B	3.99B	6.17B	5.60B
Investing Cash Flow	0.00	-7.28B	-307.00M	-270.45M	-1.55B	-159.74M
Financing Cash Flow	0.00	-2.08B	-2.09B	-2.38B	-1.57B	-1.16B

Mizuho Medy Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1753.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Positive. The current price of 1753 is below the 20-day moving average (MA) of 1821.50, below the 50-day MA of 1827.72, and above the 200-day MA of 1619.53, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 52.94 is Neutral, neither overbought nor oversold. The STOCH value of 70.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4595.

Mizuho Medy Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4595	81 Outperform	¥35.07B	9.48	―	6.29%	-12.03%	-19.61%
4886	76 Outperform	¥73.77B	8.62	―	2.52%	5.44%	-20.33%
4534	73 Outperform	¥119.10B	12.60	4.81%	2.34%	4.35%	48.30%
4554	68 Neutral	¥63.78B	35.63	5.01%	2.39%	12.01%	-51.38%
4539	64 Neutral	¥6.23B	11.64	―	3.21%	4.25%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4892	48 Neutral	¥6.10B	-12.20	―	―	56.17%	-11.63%